Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

BACKGROUND: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouvinov, Keren, Levanon, Eran, Peer, Avivit, Sarfaty, Michal, Sarid, David, Neiman, Victoria, Grikshtas, Eduard, Rosenbaum, Eli, Kushnir, Igal, Talmor, Barak, Friger, Michael, Zarbiv, Yonaton, Gez, Eli, Dresler, Hadas, Shalata, Walid, Meirovitz, Amichay, Shrem, Noa Shani, Yakobson, Alexander, Mermershtain, Wilmosh, Keizman, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244774/
https://www.ncbi.nlm.nih.gov/pubmed/37293597
http://dx.doi.org/10.3389/fonc.2023.1151701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244774/
https://www.ncbi.nlm.nih.gov/pubmed/37293597
http://dx.doi.org/10.3389/fonc.2023.1151701

Ejemplares similares